[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cancer-recurrence\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cancer-recurrence":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,46,80,113],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100547208","opioid-free-anaesthesia-in-breast-cancer-surgery-100547208",false,"NCT06404983","Opioid-free Anaesthesia in Breast Cancer Surgery","A Comparative Evaluation of Opioid Free Anaesthesia Technique Versus the Conventional Technique in Oncological Breast Surgery","Inclusion Criteria:\n\n* adult patients\n* breast cancer surgery (mastectomy, lumpectomy, with or without lymph node excision) under general anaesthesia\n\nExclusion Criteria:\n\n* under 18 years\n* patient refusal\n* opioid use (systemic or not) for any reason (e.g., chronic malignant pain)\n* language barrier (difficulty in communicating in Greek language)\n* allergy to the administered agents\n* severe arrhythmia or other serious cardiac disease\n* severe liver and kidney failure\n* dementia, psychiatric diseases, and\u002For preoperative cognitive impairment","FEMALE","18 Years","99 Years",{"count":20,"type":21},200,"ESTIMATED","INTERVENTIONAL",[24],"NA","Background:\n\nVarious analgesic modalities are adopted for perioperative analgesia in breast cancer surgeries. Opioid-free and opioid-sparing techniques are gaining popularity due to the lack of opioid-dependent undesirable effects, including respiratory depression, urinary retention, nausea and vomiting, constipation, itching, opioid-induced hyperalgesia, tolerance, addiction, and immune system disorders.\n\nThe goal of this prospective randomized clinical trial is to investigate the impact of opioid-free anaesthesia (OFA) versus conventional general anaesthesia (CGA) on postoperative analgesic requirements after breast cancer surgery (lumpectomy\u002Fmastectomy, with or without axillary lymph node excision).\n\nSecondary objectives include comparative perioperative evaluation of cognitive function and postoperative adverse events during the first 48 hours atfter surgery. Comparative evaluation of intraoperative haemodynamics and hospital length of stay are also secondary objectives, as well as the incidence of neuropathic pain assessed by validated questionnaires at 3 and 6 months postoperatively.\n\nDuring the preoperative screening, body measurements, age, gender, ASA (American Society of Anesthesiologists) physical status classification, educational level (using a 6-level scale: elementary, middle school, high school, higher education, higher education, and postgraduate\u002Fdoctoral degree), home medication, and comorbidities (using the Charlson Comorbidity Index) are recorded.\n\nIntraoperatively, the duration of anaesthesia, duration of surgery, associated intraoperative data (e.g., haemodynamic instability, adverse effects associated with protocol-administered pharmaceutical agents, etc.), and medications administered (type and quantity) are recorded.\n\nThe investigators expect to recruit at least 100 participants per group.",[27,28,29,30,31,32],"Breast Cancer","Anesthesia","Pain, Postoperative","Pain, Chronic","Opioid Free Anaesthesia","Cancer Recurrence","RECRUITING","2026-05-01",{"date":36,"type":37},"2026-05-06","ACTUAL",{"date":39,"type":37},"2022-12-28",{"date":41,"type":21},"2027-09-12",{"name":43,"class":44},"University of Ioannina","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":53,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":64,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":45},"100619222","parental-support-intervention-in-an-advanced-oncological-context-100619222","NCT07341815","Parental Support Intervention in an Advanced Oncological Context","Efficacy of a Parental Support Intervention to Improve Communication of Advanced Cancer Patients With Adolescents and Young Adults","Inclusion Criteria:\n\n* Metastatic cancer, recurrence of cancer or certain types of hematological cancer (chronic disease, acute leukemia, multiple myeloma or lymphoma recurrence)\n* Have at least one child aged between 10 and 25 years\n* Wish to benefit from a psychological intervention about communication with their children about cancer or its consequences\n* Able to read and speak French\n* Accept to give their written informed consent\n\nExclusion Criteria:\n\n* Severe neurological disorder\n* Severe psychiatric disorder\n* (Pre-)terminal phase of cancer disease","ALL",{"count":55,"type":21},120,[24],"This prospective, two-arm randomized trial compares a psycho-educational program to a psycho-educational and experiential program for parents with advanced cancer. These two interventions aim to support parent-child communication about cancer, but we hypothesize that the combined intervention will be more effective for all studied communication variables.",[59,32,60,61,62,63],"Metastatic Cancer","Hematological Cancer","Parent-Child Relations","Parenting","Communication",[65,66,67,68,69,70],"Parental cancer","Parent-child communication","Parenting intervention","Advanced cancer","Adolescent Young Adult (AYA)","Uncertainty","2026-01-07",{"date":73,"type":37},"2026-01-14",{"date":75,"type":37},"2022-05-27",{"date":77,"type":21},"2026-12",{"name":79,"class":44},"Université Libre de Bruxelles",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":53,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":91,"briefSummary":93,"conditions":94,"keywords":99,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":112},"100403385","phase-4-impact-of-remimazolam-on-prognosis-after-bladder-cancer-surgery-100403385","NCT04532606","Impact of Remimazolam on Prognosis After Bladder Cancer Surgery","Impact of Remimazolam Tosilate for General Anesthesia on Prognosis After Bladder Cancer Surgery: a Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age ≥50 years and \\\u003C90 years;\n2. Preoperative diagnosis is non-muscle-invasive bladder cancer(Ta-T1);\n3. Scheduled to undergo transurethral resection of bladder tumor;\n4. Agree to participate, and provide written informed consent.\n\nExclusion Criteria:\n\n1. Refuse to participate;\n2. Emergent surgery;\n3. Combined with other malignant tumors;\n4. Use of benzodiazepines for 1 week within the last month before surgery;\n5. Preoperative history of schizophrenia, epilepsy, parkinsonism or myasthenia gravis;\n6. Inability to communicate in the preoperative period due to coma, profound dementia, language barrier, or end-stage disease;\n7. Critical illness (preoperative American Society of Anesthesiologists physical status classification ≥IV), severe hepatic dysfunction (Child-Pugh class C), or severe renal dysfunction (undergoing dialysis before surgery);\n8. The purpose of surgery is to make a diagnosis or preoperative judgement is that tumor cannot be completely removed.","50 Years","90 Years",{"count":90,"type":21},1128,[92],"PHASE4","Bladder cancer is one of the most common genitourinary cancers. Transurethral resection of bladder tumor (TURBT) is the standard therapy for nonmuscle invasive bladder cancer. However, patients after TURBT are at risk for recurrence and progression. Benzodiazepines are proved to inhibit proliferation of multiple types of cancer cells in vitro. Delirium is an acute onset and transient cerebral dysfunction and is associated with worse outcomes. Previous studies indicated that benzodiazepines increase incidence of postoperative delirium. Remimazolam is a new benzodiazepine with rapid onset and ultra-short activity. The aims of this study are to explore the impact of remimazolam for general anesthesia on emergency delirium and recurrence-free survival in patients undergoing bladder cancer surgery.",[95,96,97,98,32],"Benzodiazepines","Bladder Cancer","Delirium","Surgery",[100,96,98,101,102],"Remimazolam","Emergence Delirium","Recurrence-free Survival","2025-07-29",{"date":105,"type":37},"2025-07-30",{"date":107,"type":37},"2021-02-05",{"date":109,"type":21},"2026-10",{"name":111,"class":44},"Peking University First Hospital",6,{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":119,"eligibilityCriteria":120,"healthyVolunteers":11,"sex":121,"minAge":17,"maxAge":122,"enrollmentInfo":123,"targetDuration":4,"studyType":22,"phases":125,"briefSummary":127,"conditions":128,"keywords":130,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":145},"100411782","phase-3-psma-pet-guided-hypofractionated-salvage-prostate-bed-radiotherapy-100411782","NCT04642027","PSMA-PET Guided Hypofractionated Salvage Prostate Bed Radiotherapy","PSMA-PET Guided Hypofractionated Salvage Prostate Bed Radiotherapy of Biochemical Failure After Radical Prostatectomy for Prostate Cancer","PERYTON","Inclusion Criteria:\n\n* Patients with prostate adenocarcinoma treated with radical prostatectomy;\n* Tumour stage pT2-4, R0-1, pN0, or cN0, cNx according to the UICC TNM 2009, only with Gleason score available;\n* No lymph node or distant metastases. A recent PSMA-PET scan (\\\u003C 60 days) without evidence of lymph node or distant metastases;\n* PSA progression after prostatectomy defined as two consecutive rises with the final PSA \\> 0.1 ng\u002FmL or 3 consecutive rises. The first value must be measured at least 6 weeks after radical prostatectomy;\n* PSA at inclusion \\\u003C 1.0 ng\u002FmL;\n* WHO performance status 0-2 at inclusion;\n* Age at inclusion between 18 and 80 years;\n* Written (signed and dated) informed consent prior to registration.\n\nExclusion Criteria:\n\n* Prior pelvic irradiation, (chemo)hormonal therapy or orchiectomy;\n* Previous or concurrent active invasive cancers other than superficial non-melanoma skin cancers;\n* Patients with positive nodes or with distant metastases based on the surgical specimen of lymphadenectomy or the following minimum diagnostic workup: PSMA-PET\u002FCT scan, 60 days prior to registration;\n* Double-sided metallic hip prosthesis;\n* Inability or unwillingness to understand the information on trial-related topics, to give informed consent or to fill out QoL questionnaires.","MALE","80 Years",{"count":124,"type":21},538,[126],"PHASE3","After radical prostatectomy approximately 15-40% of men develop a biochemical recurrence (BR) within 5 years.\n\nThe standard treatment of post-prostatectomy BR is salvage external beam radiation therapy (sEBRT). sEBRT can provide long-term disease control; with 5 year biochemical progression-free survival (bPFS) up to 60% and with most treatment failures in the first 2 years after sEBRT.\n\nThe main goal of this project is to investigate whether the oncologic outcome in patients with post-prostatectomy recurrent PCa can be improved, by increasing the biological effective radiation dose using a hypofractionated schedule of 20 x 3 = 60 Gy.\n\nThe study is designed as a prospective open phase III randomized multicenter trial. All patients with biochemical recurrence with a PSA \\\u003C 1.0 ng\u002Fml after radical prostatectomy for prostate cancer without evidence of lymph nodes or distance metastases will be included. PSA progression after prostatectomy defined as two consecutive rises with the final PSA \\> 0.1 ng\u002FmL or three consecutive rises will be included.\n\nAll eligible patients will be randomized to one of the following two treatment arms:\n\nArm 1 = Conventional sEBRT to apply a total dose of 70 Gy in 35 daily fractions of 2 Gy during 7 weeks.\n\nArm 2 = Hypofractionated sEBRT to apply a total dose of 60 Gy in 20 fractions of 3 Gy during 4 weeks.\n\nThe primary endpoint will be the 5-year progression-free survival (PFS) after treatment.",[129,32],"Prostate Cancer",[131,132,133,134,135],"PSMA-PET\u002FCT","Salvage","Hypofractionation","Radiotherapy","Prostatectomy","2024-02-26",{"date":138,"type":37},"2024-02-28",{"date":140,"type":37},"2020-09-01",{"date":142,"type":21},"2030-09-01",{"name":144,"class":44},"University Medical Center Groningen",13]